Fate Therapeutics 3Q 2026: Revenue $0, EPS ($0.25) — 10-Q Summary

Fate Therapeutics reported no revenue in 3Q 2026, down from $1.74M a year earlier, due to completed performance obligations under its Ono agreement. Net loss narrowed to $30.69M from $32.25M, with lower R&D and G&A expenses. The company initiated a Phase 2 trial for FT819 and expects $139.1M in cash to fund operations for at least 12 months.

Original reporting
Published Nov 5, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fate Therapeutics 3Q 2026: Revenue $0, EPS ($0.25) — 10-Q Summary — source image
Decision brief

The 30-second read

$FATEBearishMed
01

Why it matters

The earnings release provides fresh data on cash runway and trial progress, essential for valuation models.

02

Market read

First‑time disclosure of Q3 2026 results for a small‑cap biotech, influencing short‑term price action and sector sentiment.

03

What to watch

Potential upcoming collaborations or pipeline milestones not disclosed may offset the revenue shortfall.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Fate Therapeutics filed its 10‑Q for Q3 2026, reporting the completion of its Ono collaboration obligations and initiating a Phase 2 trial for lupus nephritis.

Company-level read

Ticker impact

$FATEBearishHigh confidence
Context

Fate Therapeutics disclosed its 3Q 2026 results with zero collaboration revenue and a narrowed net loss.

Expected impact

likely pressure as the market prices in zero revenue and ongoing loss.

Evidence & confidence

Zero collaboration revenue signals reduced near‑term cash flow; despite lower expenses, the loss remains sizable.

Market effects

Biotech sector may see modest sentiment dip as a peer reports no revenue.

US biotech investors could adjust exposure in the short term.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

The loss narrowing and expense cuts could be seen as a positive operational trend.

Key entities

  • Fate Therapeutics Inc.

    US‑listed biotech company (ticker FATE).

  • Ono Pharmaceutical

    Collaborator whose agreement obligations were fulfilled.

Related articles

$FATEHigh

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be fa

$FATEMed

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera

$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

$FATEMed

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated